Last Updated: 23/02/2026
Dual-active-ingredient insecticide-treated ceiling nets: a novel vector control approach to combat artemisinin-resistant Plasmodium falciparum towards malaria elimination in Africa
Objectives
This project will evaluate the effectiveness of two types (Olyset® Plus and Interceptor® G2) of double insecticide-treated roof nets in Kagera, Tanzania, where malaria transmission is intense and artemisinin-resistant parasites are present. In addition to the effectiveness, economic and socio-cultural analyses will also be conducted to determine the feasibility of using insecticide-treated roof nets beyond the study area.
Noushin Emami
Billy Ngasala
Chim W. Chan
Mtakai Ngara
Anders Bjorkman
Yura K. Ko
Malaria is caused by Plasmodium parasites transmitted by Anopheles mosquitoes. In 2023, malaria caused 263 million cases of illness and 597,000 deaths, over 95% of which occurred in Africa. Since the mid-2000s, insecticidal nets (ITNs) and artemisinin-based combination therapies (ACTs) have been the mainstay of malaria control, but insecticide resistance in mosquitoes and artemisinin resistance in parasites are increasing, contributing to the recent rise in malaria cases and deaths. In addition, ITN use is suboptimal; many school-age children do not sleep in beds, making conventional ITN use impractical. New tools and strategies are needed to complement current malaria interventions. Insecticide-treated ceiling nets provide barriers that prevent mosquitoes from entering through open skylights and kill mosquitoes resting on ceilings and walls after a blood meal. Because they are continuously installed and cover the entire house, they can protect all its inhabitants at all times indoors, without any intervention from the inhabitants. These insecticide-treated roof nets represent a new approach whose effectiveness in different environments has not been evaluated. The results of this research will be sent to the World Health Organization for evaluation and recommendation as a new vector control to limit the new increasing threat of malaria.
Jan 2026 — Dec 2029
$511,078


